2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1530

CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Abstract Number: 1531

Tofacitinib Show Similar Retention When Used with and without Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Abstract Number: 1532

Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
Abstract Number: 1533

Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
Abstract Number: 1534

Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
Abstract Number: 1535

Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits
Abstract Number: 1536

Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients
Abstract Number: 1537

Frequency and Duration of Early Non-Serious Adverse Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 5 Mg Twice Daily As Monotherapy and Combination Therapy
Abstract Number: 1538

Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Abstract Number: 1539

Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
Abstract Number: 1540

Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
Abstract Number: 1541

The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
Abstract Number: 1542

Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Abstract Number: 1543

The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
Abstract Number: 1544

Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].